HB0028 / Zhejiang Huahai Pharma, Huaota Biopharm, Huabo Biopharmaceutical Technology - LARVOL DELTA

A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors. (ASCO 2024) - P1/2 | "HB0028 was generally well tolerated, and therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. Based on these data, a phase II prospective clinical trial is being planned in specific cancer."

Clinical • Metastases • P1/2 data • PK/PD data • Anemia • Cervical Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Liver Cancer • Lung Cancer • Oncology • Solid Tumor • TGFB1

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.

IO biomarker • Metastases • New P1/2 trial • Cervical Cancer • Oncology • Solid Tumor • PD-L1 • TGFB1